The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission permitted using an esketamine nasal spready underneath the brand name Spravato to take care of depression. Nevertheless, as of 2021, ketamine has not been permitted because of the FDA to take care of melancholy or other mental health disorders, and as a consequence,